Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma.
Dalla Palma B, Marchica V, Pedrazzoni M, Accardi F, Notarfranchi L, Goldoni M, De Luca F, Costa F, Storti P, Toscani D, Sammarelli G, Bonomini S, Aversa F, Giuliani N. Dalla Palma B, et al. Among authors: toscani d. Br J Haematol. 2018 Dec;183(5):812-815. doi: 10.1111/bjh.15026. Epub 2017 Nov 16. Br J Haematol. 2018. PMID: 29143308 Free article. No abstract available.
Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.
Bolzoni M, Donofrio G, Storti P, Guasco D, Toscani D, Lazzaretti M, Bonomini S, Agnelli L, Capocefalo A, Dalla Palma B, Neri A, Nicolini F, Lisignoli G, Russo F, Colla S, Aversa F, Giuliani N. Bolzoni M, et al. Among authors: toscani d. Leukemia. 2013 Feb;27(2):451-63. doi: 10.1038/leu.2012.190. Epub 2012 Jul 11. Leukemia. 2013. PMID: 22781592
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.
Bolzoni M, Storti P, Bonomini S, Todoerti K, Guasco D, Toscani D, Agnelli L, Neri A, Rizzoli V, Giuliani N. Bolzoni M, et al. Among authors: toscani d. Exp Hematol. 2013 Apr;41(4):387-97.e1. doi: 10.1016/j.exphem.2012.11.005. Epub 2012 Nov 23. Exp Hematol. 2013. PMID: 23178378 Free article.
Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.
Storti P, Bolzoni M, Donofrio G, Airoldi I, Guasco D, Toscani D, Martella E, Lazzaretti M, Mancini C, Agnelli L, Patrene K, Maïga S, Franceschi V, Colla S, Anderson J, Neri A, Amiot M, Aversa F, Roodman GD, Giuliani N. Storti P, et al. Among authors: toscani d. Leukemia. 2013 Aug;27(8):1697-706. doi: 10.1038/leu.2013.24. Epub 2013 Jan 24. Leukemia. 2013. PMID: 23344526
New insights into osteogenic and chondrogenic differentiation of human bone marrow mesenchymal stem cells and their potential clinical applications for bone regeneration in pediatric orthopaedics.
Giuliani N, Lisignoli G, Magnani M, Racano C, Bolzoni M, Dalla Palma B, Spolzino A, Manferdini C, Abati C, Toscani D, Facchini A, Aversa F. Giuliani N, et al. Among authors: toscani d. Stem Cells Int. 2013;2013:312501. doi: 10.1155/2013/312501. Epub 2013 May 23. Stem Cells Int. 2013. PMID: 23766767 Free PMC article.
The osteoblastic niche in the context of multiple myeloma.
Toscani D, Bolzoni M, Accardi F, Aversa F, Giuliani N. Toscani D, et al. Ann N Y Acad Sci. 2015 Jan;1335:45-62. doi: 10.1111/nyas.12578. Epub 2014 Nov 25. Ann N Y Acad Sci. 2015. PMID: 25424768 Review.
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.
Toscani D, Palumbo C, Dalla Palma B, Ferretti M, Bolzoni M, Marchica V, Sena P, Martella E, Mancini C, Ferri V, Costa F, Accardi F, Craviotto L, Aversa F, Giuliani N. Toscani D, et al. J Bone Miner Res. 2016 Apr;31(4):815-27. doi: 10.1002/jbmr.2741. Epub 2015 Dec 14. J Bone Miner Res. 2016. PMID: 26551485 Free article.
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.
Storti P, Toscani D, Airoldi I, Marchica V, Maiga S, Bolzoni M, Fiorini E, Campanini N, Martella E, Mancini C, Guasco D, Ferri V, Donofrio G, Aversa F, Amiot M, Giuliani N. Storti P, et al. Among authors: toscani d. Haematologica. 2016 Mar;101(3):e107-10. doi: 10.3324/haematol.2015.133736. Epub 2015 Dec 11. Haematologica. 2016. PMID: 26659917 Free PMC article. No abstract available.
41 results